---
title: "China Meheco: Subsidiary Tianfang Pharmaceutical's Nicardipine Tablets intend to be selected for the 11th batch of national centralized drug procurement"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/263051343.md"
description: "China Meheco's subsidiary Tianfang Pharmaceutical Co., Ltd. participated in the bidding for the 11th batch of national centralized drug procurement, with its Nicardipine tablets expected to be selected, specifications of 5mg, priced at 2.59 yuan/box, with a procurement period of 3 years. Tianfang Pharmaceutical's audited operating income for 2024 is approximately 52.47 million yuan. If successful in the bid, it will help expand sales scale, increase market share, and have a positive impact on the company's future performance"
datetime: "2025-10-28T09:53:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263051343.md)
  - [en](https://longbridge.com/en/news/263051343.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263051343.md)
---

# China Meheco: Subsidiary Tianfang Pharmaceutical's Nicardipine Tablets intend to be selected for the 11th batch of national centralized drug procurement

China Meheco announced that its subsidiary Tianfang Pharmaceutical Co., Ltd. participated in the bidding for the 11th batch of national centralized drug procurement, and its Nicardipine tablets are expected to be selected. The product specification is 5mg, indicated for angina pectoris, with a packaging quantity of 48 tablets/box, and the proposed winning price is 2.59 yuan/box. The procurement period is 3 years, from 2026 to December 31, 2028. Tianfang Pharmaceutical's audited operating income for the year 2024 is approximately 52.47 million yuan, and the unaudited operating income for the first half of 2025 is approximately 15.82 million yuan. If awarded the bid, it will help expand product sales scale, increase market share, and have a positive impact on the company's future performance

### Related Stocks

- [600056.CN](https://longbridge.com/en/quote/600056.CN.md)

## Related News & Research

- [China Telecom's Shares Rise After Becoming Last of Country's Big Three Telcos to Roll Out Token Plans](https://longbridge.com/en/news/286859736.md)
- [CHINA JAN-APRIL FISCAL REVENUES +3.5% YR/YR](https://longbridge.com/en/news/287035681.md)
- [WHO chief: Approved 3.4mn USD for ebola response](https://longbridge.com/en/news/287039699.md)
- [China's Bio-Thera Gets US Nod for Golimumab Biosimilar](https://longbridge.com/en/news/286880573.md)
- [New York Governor Signs Bills To Preserve Mandatory Vaccines](https://longbridge.com/en/news/286947583.md)